Clinical Trials Logo

Migraine clinical trials

View clinical trials related to Migraine.

Filter by:

NCT ID: NCT04461795 Completed - Migraine Clinical Trials

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

Start date: December 1, 2020
Phase: Phase 4
Study type: Interventional

This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.

NCT ID: NCT04458857 Completed - Migraine Clinical Trials

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Start date: July 15, 2020
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab. The total duration of the study is planned to be up to 51 months.

NCT ID: NCT04437199 Completed - Migraine Clinical Trials

Tricaprilin Phase 2 Pilot Study in Migraine

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of tricaprilin as AC-SD-03 compared with placebo for the reduction of migraine in participants with frequent migraine.

NCT ID: NCT04418765 Completed - Migraine Clinical Trials

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

DELIVER
Start date: June 1, 2020
Phase: Phase 3
Study type: Interventional

Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.

NCT ID: NCT04413110 Completed - Migraine Clinical Trials

PSG and Neuroendocrine Hormones in Subjective Cognitive Impaired Patients With Transformed Migraine

Start date: April 1, 2019
Phase:
Study type: Observational

Transformed migraine is the most common and challenging subtype of chronic daily headache disorders35. Patients with transformed migraine often report an evolutionary process that occurs over months or years in which headaches increase in frequency, change characteristics and ultimately result in patterns of daily or near-daily headaches resembling a mixture of tension-type headache and migraine.

NCT ID: NCT04406649 Completed - Migraine Clinical Trials

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

ASCEND
Start date: September 14, 2020
Phase: Phase 3
Study type: Interventional

Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

NCT ID: NCT04401137 Completed - Migraine Clinical Trials

The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects

Start date: July 1, 2020
Phase: Phase 1
Study type: Interventional

To evaluate pharmacokinetic/pharmacodynamic characteristics and safety of QDX after single oral administration in healthy Korean male subjects

NCT ID: NCT04360044 Completed - Migraine Clinical Trials

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

Start date: November 20, 2020
Phase: Phase 2
Study type: Interventional

This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.

NCT ID: NCT04355117 Completed - Migraine Clinical Trials

A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

Start date: June 17, 2020
Phase: Phase 3
Study type: Interventional

This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home. Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses. The first dose will be self-administered at the trial site under the supervision of the investigator and the second dose will be self-administered at home.

NCT ID: NCT04341298 Completed - Migraine Clinical Trials

Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

Start date: April 6, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application, when compared to a control device.